Abstracts tagged "dermatomyositis"

Abstract Number: 0710 • ACR Convergence 2021
Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease
Kristofer Andreasson¹ and Helene Alexanderson², ¹Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To analyze for differences in quadriceps maximal isometric voluntary contraction (MVIC), muscle endurance (ME), muscle mass and fat mass (m. vastus lateralis, mid-thigh) in…
Abstract Number: 0513 • ACR Convergence 2021
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
DeAnna Diaz¹, Thomas Vazquez², Christina Bax³, Jay Patel⁴, Madison Grinnell⁵, Emily Keyes⁶, Yubin Li⁵ and Victoria Werth⁷, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, ⁴Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ⁵Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁶Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
Abstract Number: 0713 • ACR Convergence 2021
MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients
Eveline Van Gompel¹, Catia Cerqueira², Karine Chemin³, Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria⁴, khaled amara⁵, Edvard Wigren⁶, Susanne Gräslund⁶, Ellen De Langhe⁷, Olivier Benveniste⁸ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²4Dcell, Montreuil, France, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷KU Leuven, Leuven, Belgium, ⁸UPMC, Paris, France
Background/Purpose: The presence of anti-melanoma differentiation associated protein 5 (MDA5) autoantibodies in myositis patients is associated with mucocutaneous ulcerations, (rapidly progressing) interstitial lung disease (RPILD),…
Abstract Number: 1085 • ACR Convergence 2020
Pain in Myositis Is Associated with the Disease Activity
Anjana Chandrasekhara Pillai¹, Chester Oddis², Siamak Moghadam-Kia³, Dana Ascherman⁴, Nicole Neiman⁵, Diane Koontz⁵, Ren Dianxu⁵ and Rohit Aggarwal⁴, ¹UPMC Mckeesport, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵UPMC, Pittsburgh, PA
Background/Purpose: Pain in myositis is poorly studied and multifactorial relating to muscle weakness, arthritis, myofasciitis, fibromyalgia or other co-morbidities. We sought to prospectively evaluate patient-reported…
Abstract Number: 1087 • ACR Convergence 2020
Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
Yubin Li¹, Christina Bax², Jay Patel³, Adarsh Ravishankar³, Krisha Desai⁴, Majid Zeidi⁴, Muhammad Bashir⁴ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Julie Paik¹, Jemima Albayda¹, Eleni Tiniakou¹, Grazyna Purwin¹, Andrew Koenig² and Lisa Christopher-Stine¹, ¹Johns Hopkins University, Baltimore, MD, ²Pfizer Inc, New York City, NY
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
Abstract Number: 0531 • ACR Convergence 2020
The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records
Sunali Goonesekera¹, Ankit Bansal¹, Swarali Tadwalkar² and Alison Isherwood³, ¹Decision Resources Group, Part of Clarivate, Boston, MA, ²Decision Resources Group, part of Clarivate, Bangolore, India, ³Decision Resources Group, part of Clarivate, London, United Kingdom
Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis⁸, Elena Schiopu⁹, Jiří Vencovský¹⁰, Beckmann Irene¹¹, Clodi Elisabeth¹¹, Todd Levine¹² and and the ProDERM Investigators¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of California, Los Angeles, Los Angeles, CA, ³Städtisches Klinikum Karlsruhe, Karlsruhe, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Michigan Medicine, Ann Arbor, MI, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria, ¹²Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹³Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…
Abstract Number: 1138 • ACR Convergence 2020
Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis
Madison Wolfe¹, Amanda Robinson², Jin-Shei Lai³, Theresa Coles⁴, Elizabeth Gray³, Rowland Chang³, David Cella³ and Kaveh Ardalan⁵, ¹Creighton University School of Medicine, Omaha, NE, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Duke University, Durham, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Juvenile myositis (JM) causes weakness, rashes, pain, and fatigue, thereby impacting health-related quality of life (HRQoL). Patient-Reported Outcomes Measurement Information System (PROMIS®) measures have…
Abstract Number: 0956 • ACR Convergence 2020
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
Alex Tsoi¹, Mehrnaz Gharaee-Kermani², Celine Berthier¹, Tori Nault³, Grace Hile², Shannon Estadt⁴, Matthew Patrick¹, Rachael Wasikowski¹, Allison Billi¹, Lori Lowe¹, Tamra Reed¹, Johann Gudjonsson⁵ and J. Michelle Kahlenberg⁶, ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Canton, MI, ⁴University of Michigan, Ypsilanti, MI, ⁵University of Michigan, Ann ArborUniversity of Michigan, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin lesions in dermatomyositis (DM) patients are common, frequently refractory, and have prognostic significance. Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE)…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1555 • ACR Convergence 2020
18F-NaF PET/CT Identifies Active Calcium Uptake in Calcinosis Due to Dermatomyositis and Scleroderma
Carrie Richardson¹, Mehrbod Javadi², Ami Shah³, Lilja Solnes², Fredrick Wigley⁴, Laura Hummers⁵ and Lisa Christopher-Stine⁶, ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins Univerisity, Ellicott City, MD, ⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: Ectopic soft tissue deposition of hydroxyapatite (calcinosis) is a frequent and morbid complication of dermatomyositis and scleroderma with no known effective pharmacologic treatment. 18F-NaF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].